Aqua Metals stock price target raised to $7 from $3 at Benchmark

Published 14/08/2025, 14:42
Aqua Metals stock price target raised to $7 from $3 at Benchmark

Investing.com - Benchmark raised its price target on Aqua Metals (NASDAQ:AQMS) to $7.00 from $3.00 on Thursday, while maintaining a Speculative Buy rating on the stock. The company, currently trading at $4.19 with a market cap of just $4.05 million, has shown strong momentum with a 12.5% gain over the past week, according to InvestingPro data.

The price target increase follows Aqua Metals’ second-quarter 2025 results and subsequent update on its commercialization progress.

Benchmark noted that Aqua Metals has achieved best-in-class lithium carbonate purity with less than 30 ppm fluorine content through its AquaRefining process.

The research firm highlighted validation that Aqua Metals’ process can match Chinese hydrometallurgical costs while operating at approximately half the cost of traditional U.S. methods.

While Aqua Metals remains pre-revenue at scale, Benchmark cited the company’s superior product specifications, cost competitiveness, and IP protection as factors creating a "high-risk, high-reward investment profile" dependent on securing offtake, licensing, and joint venture agreements.

In other recent news, Aqua Metals Inc . reported a net loss of $6.8 million, translating to $7.44 per share, during its Q2 2025 earnings call. The company announced significant operational changes aimed at conserving cash, including the sale of assets and workforce reductions. These developments come as part of Aqua Metals’ strategic shift to streamline operations and improve financial stability. The company’s efforts reflect a broader trend in the industry to adapt to changing market conditions. Aqua Metals’ management is focusing on strategic realignments to enhance operational efficiency. Despite the financial challenges, the company remains committed to its long-term goals. Investors will be closely monitoring how these changes impact Aqua Metals’ financial health in the upcoming quarters.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.